Login
$AGIO
$29.55 -$0.60 (1.99%) After hours

$AGIO 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and u...

30 Jul 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., July 30, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ...

18 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

29 Apr 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., Apr. 29, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ...

12 Feb 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., Feb. 12, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ...

12 Jan 2026 8-K: Regulation FD Disclosure

J.P. Morgan Healthcare Conference 2026 Agios Pharmaceuticals Brian Goff, Chief Executive Officer 14 January 2026 Exhibit 99.2

30 Oct 2025 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., October 30, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results a...

04 Aug 2025 8-K: Regulation FD Disclosure

Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) is aware of the securities analyst report published on August 4, 2025 (the “Analyst Report”), detailing recent PYRUKYND® data from the U.S. Food and Drug Administration’s (“FDA”) Adv...

31 Jul 2025 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., July 31, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ...

08 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

18 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

01 May 2025 8-K: Results of Operations and Financial Condition

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia,

13 Feb 2025 8-K: Results of Operations and Financial Condition

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with

13 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 Jan 2025 8-K: Regulation FD Disclosure

J.P. Morgan Healthcare Conference Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 15, 2025 Exhibit 99.2

06 Jan 2025 8-K: Regulation FD Disclosure

On January 3, 2025, the U.S. Food and Drug Administration approved an update to the U.S. Prescribing Information (“USPI”) for PYRUKYND® (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase (“PK”) deficiency. T...

31 Oct 2024 8-K: Results of Operations and Financial Condition

– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 –

01 Aug 2024 8-K: Results of Operations and Financial Condition

– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study;

20 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

Agios Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 20, 2024 (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting.

28 May 2024 8-K: Entry into a Material Definitive Agreement; Other Events

– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support